Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Hassan Awada; Mina Abdelmalek; Tara Cronin; Jeffrey Baron; Zakariya Kashour; Farhan Azad; Muhammad Salman Faisal; Mark Faber; Matthew Gravina; Pamela J. Sung; Steven D. Green; Amanda Przespolewski; James E. Thompson; Elizabeth A. Griffiths; Eunice S. Wang

doi:10.1038/s41408-023-00910-x

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Hassan Awada
, Mina Abdelmalek
, Tara Cronin
, Jeffrey Baron
, Zakariya Kashour
, Farhan Azad
, Muhammad Salman Faisal
, Mark Faber
, Matthew Gravina
, Pamela J. Sung
, Steven D. Green
, Amanda Przespolewski
, James E. Thompson
, Elizabeth A. Griffiths
, Eunice S. Wang

Office of Research Compliance

Roswell Park Cancer Institute
SUNY Buffalo

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English
Article number	131
Journal	Blood Cancer Journal
Volume	13
Issue number	1
DOIs	https://doi.org/10.1038/s41408-023-00910-x
State	Published - Dec 2023

Access to Document

10.1038/s41408-023-00910-x

Cite this

Awada, H., Abdelmalek, M., Cronin, T., Baron, J., Kashour, Z., Azad, F., Faisal, M. S., Faber, M., Gravina, M., Sung, P. J., Green, S. D., Przespolewski, A., Thompson, J. E., Griffiths, E. A., & Wang, E. S. (2023). Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia. Blood Cancer Journal, 13(1), Article 131. https://doi.org/10.1038/s41408-023-00910-x

@article{2b9eac2d3b44435d90bec77b699bf6b9,

title = "Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia",

author = "Hassan Awada and Mina Abdelmalek and Tara Cronin and Jeffrey Baron and Zakariya Kashour and Farhan Azad and Faisal, \{Muhammad Salman\} and Mark Faber and Matthew Gravina and Sung, \{Pamela J.\} and Green, \{Steven D.\} and Amanda Przespolewski and Thompson, \{James E.\} and Griffiths, \{Elizabeth A.\} and Wang, \{Eunice S.\}",

year = "2023",

month = dec,

doi = "10.1038/s41408-023-00910-x",

language = "English",

volume = "13",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "1",

}

Awada, H, Abdelmalek, M, Cronin, T, Baron, J, Kashour, Z, Azad, F, Faisal, MS, Faber, M, Gravina, M, Sung, PJ, Green, SD, Przespolewski, A, Thompson, JE, Griffiths, EA & Wang, ES 2023, 'Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia', Blood Cancer Journal, vol. 13, no. 1, 131. https://doi.org/10.1038/s41408-023-00910-x

TY - JOUR

T1 - Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

AU - Awada, Hassan

AU - Abdelmalek, Mina

AU - Cronin, Tara

AU - Baron, Jeffrey

AU - Kashour, Zakariya

AU - Azad, Farhan

AU - Faisal, Muhammad Salman

AU - Faber, Mark

AU - Gravina, Matthew

AU - Sung, Pamela J.

AU - Green, Steven D.

AU - Przespolewski, Amanda

AU - Thompson, James E.

AU - Griffiths, Elizabeth A.

AU - Wang, Eunice S.

PY - 2023/12

Y1 - 2023/12

UR - https://www.scopus.com/pages/publications/85169679786

U2 - 10.1038/s41408-023-00910-x

DO - 10.1038/s41408-023-00910-x

M3 - Letter

C2 - 37666807

AN - SCOPUS:85169679786

SN - 2044-5385

VL - 13

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 1

M1 - 131

ER -

Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Access to Document

Other files and links

Fingerprint

Cite this